Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL Nerve Block for Primary THA
NCT05247255Phase 1Enrolling by invitation
- Sponsor
- University of California, Los Angeles
- Start
- Mar 2022
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised trial of ropivacaine in postoperative pain (2 arms), sponsored by University of California, Los Angeles. Primary endpoint: Pain score at 48 hours. Started Mar 2022; status: enrolling by invitation.
02
Drugs
ropivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05247255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05247255.